NEW OPPORTUNITIES OF MONOTHERAPY WITH NEBILET FOR PATIENTS WITH CORONARY HEART DISEASE AND ARTERIAL HYPERTENSION
Abstract
Nebilet – is a new β-adrenoceptor blocking agent possessing both superseleсtive and NO-producing properties. Efficacy and safety of nebilet monotherapy of 5 mg/d were evaluated for 20 patients with mild and moderate essential hypertension during 8 weeks of treatment. Positive hypotensive effect was achieved in 79% of patients, average daily level of systolic and diastolic pressure decreased from 144,1±2,5 to 132,5±3,4 mm Hg and from 88,8±1,5 to 79,5±2,3 mm Hg respectively. A marked diminishing (by 80 %) of painful and painless myocardial ischemia overall duration was also observed.We didn’t reveal the inhibition of inotropic action, whereas good influencies to the remodelling of myocardium have oсcured. There were no serious adverse effects and laboratory deviations during the therapy.
About the Authors
V. M. Loyfman
Краевая клиническая больница №1 - Дальмедцентр,
Дальневосточный государственный медицинский университет,
Поликлиника Медкрайcтрой
Russian Federation
Russian Federation
A. B. Ostrovsky
Краевая клиническая больница №1 - Дальмедцентр,
Дальневосточный государственный медицинский университет,
Поликлиника Медкрайcтрой
Russian Federation
Russian Federation
Z. P. Zhirnova
Краевая клиническая больница №1 - Дальмедцентр,
Дальневосточный государственный медицинский университет,
Поликлиника Медкрайcтрой
Russian Federation
Russian Federation
L. G. Horuk
Краевая клиническая больница №1 - Дальмедцентр,
Дальневосточный государственный медицинский университет,
Поликлиника Медкрайcтрой
Russian Federation
Russian Federation
References
1. Janssens W. et al.Pharmacology of Nebivolol:a review of existing data up to August 1994.JRF Preclinical Research Report on R67555.December 1994.
2. Van Nueten L.,Walgraeve H. Pharmacodynamic effect of Nebivolol. JRF Clinical Research Report on R67555.January 1995.
3. Vanhoutte P.M.: Endothelium vasculaire et tonus vasomoteur. // Rev.Med.Liege 50 (10):418-426,1995.
4. Небилет(небиволол): клиническая фармакология и международный опыт применения. / Под ред. проф. Н.А. Мазура ,1999.
5. Stoleru L. et al. Administration of Nebivolol after coronary artery bypass in patients with altered left ventricular function. // J.Cardiovasc.Pharmacol. - 1993;22:253-258.
6. De Cree J.,Vanwelden J., Geukens H.,Verhaegen H.: Non-invasive cardiac haemodynamics of nebivoiol in men. // Acta Antwerpiensia 6(2):2-21,1989.
Review
For citations:
Loyfman V.M., Ostrovsky A.B., Zhirnova Z.P., Horuk L.G. NEW OPPORTUNITIES OF MONOTHERAPY WITH NEBILET FOR PATIENTS WITH CORONARY HEART DISEASE AND ARTERIAL HYPERTENSION. Russian Journal of Cardiology. 2000;(6):53-56. (In Russ.)
Views:
532
Email this article 